Applications to the FDA for orphan drug status for Marshall Protocol medications

Autoimmunity Research Foundation has submitted multiple applications to the Office of Orphan Products Development, a division of the FDA. The goal of submitting these applications would be to make it easier for doctors to prescribe and harder for insurance companies to deny coverage of MP medications.



  • submitted by ARF (September 2005) - Application for Orphan Drug Status for clindamycin in treatment of sarcoidosis and Post-Treatment Lyme Disease Syndrome
  • FDA approval (August 2006) - clindamycin as an orphan drug for sarcoidosis

home/publications/applications_orphan_status.txt · Last modified: 07.04.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.